Following a blockbuster year of dealmaking and a recent uptick in biotech stocks, top investors see more good news on the horizon.
Driving the momentum? Economics 101.
Biotechs rely on borrowing capital, which is a more tenuous task when interest rates are high. But interest rates have most likely peaked, with Federal Reserve officials signaling earlier this week they expected to make three cuts this year. For public biotechnology startups that have been battered by the market in recent years, this is a very good thing, Rod Nathan, portfolio manager and partner of J. Goldman & Co., said on a panel at STAT’s Breakthrough Summit East in New York on Thursday.
Click this link for the original source of this article.
Author: Allison DeAngelis and Mario Aguilar
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.